Zentalis Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Zentalis Pharmaceuticals's estimated annual revenue is currently $38M per year.
- Zentalis Pharmaceuticals's estimated revenue per employee is $193,750
- Zentalis Pharmaceuticals's total funding is $517.1M.
Employee Data
- Zentalis Pharmaceuticals has 196 Employees.
- Zentalis Pharmaceuticals grew their employee count by 0% last year.
Zentalis Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, President and Director | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Chief People Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Executive Assistant to Chief Medical Officer | Reveal Email/Phone |
6 | Chief Strategy Officer | Reveal Email/Phone |
7 | VP, Clinical Pharmacology | Reveal Email/Phone |
8 | VP, Data Management | Reveal Email/Phone |
9 | VP, Discovery Biology | Reveal Email/Phone |
10 | SVP, Clinical Development | Reveal Email/Phone |
Zentalis Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Zentalis Pharmaceuticals?
Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
keywords:N/A
$517.1M
Total Funding
196
Number of Employees
$38M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zentalis Pharmaceuticals News
Pfizer is throwing its weight behind Zentalis Pharmaceuticals' synthetic lethality candidate, making a $25 million investment in its new partner and...
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic...
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics...
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financing of Zentera Therapeutics, a biopharmaceutical company ...
NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the completion of an $85 million Series C fin ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $52.4M | 196 | 23% | N/A |
#2 | $62.5M | 196 | -2% | N/A |
#3 | $56.4M | 196 | 20% | N/A |
#4 | $30.8M | 196 | 5% | N/A |
#5 | $55M | 196 | -1% | N/A |